Repligen's Valuation Crossroads: Ordering Stabilizes, But Can Growth Segments Justify the Premium?
As Repligen signals a steadying order book from key biopharma clients and strength in gene therapy, investors are weighing its lofty valuation against a mixed performance record and sector headwinds.